<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759846</url>
  </required_header>
  <id_info>
    <org_study_id>W00090GE101</org_study_id>
    <nct_id>NCT04759846</nct_id>
  </id_info>
  <brief_title>Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma</brief_title>
  <official_title>Open Label, Phase I Study to Evaluate Impact of Moderate and Severe Hepatic Impairment on the Pharmacokinetics and Safety of Encorafenib in Combination With Binimetinib in Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia,&#xD;
      Japan and Switzerland for the treatment of adult patients with unresectable or metastatic&#xD;
      melanoma with BRAF V600 mutation.&#xD;
&#xD;
      The main objective of this study is to find a safe and effective dose of encorafenib in&#xD;
      combination with binimetinib for patients who have BRAF-mutant metastatic or unresectable&#xD;
      melanoma with hepatic dysfunction (i.e. moderate or severe impairment).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multicentre, phase I study to evaluate the impact of moderate and&#xD;
      severe hepatic impairment (HI) on the pharmacokinetics and safety of encorafenib in&#xD;
      combination with binimetinib, in adult patients with unresectable or metastatic BRAF&#xD;
      V600-mutant melanoma.&#xD;
&#xD;
      For each participant, the treatment period will be split in 2 phases:&#xD;
&#xD;
        -  a HI assessment phase assessing the impact of hepatic impairment after a single dose&#xD;
           (Day 1) and after repeated doses (Day 15).&#xD;
&#xD;
        -  a post-HI assessment phase: after completing the HI assessment phase, participants may&#xD;
           continue treatment in the post-HI assessment phase until disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Participants with hepatic impairment will be enrolled sequentially according to their&#xD;
      severity. The study will start first in participants with normal hepatic function and&#xD;
      moderate hepatic impairment respectively.&#xD;
&#xD;
      Participants will be assigned to one of the following 3 study groups:&#xD;
&#xD;
        -  Group with normal hepatic function: 4 participants&#xD;
&#xD;
        -  Group with moderate hepatic impairment (Child-Pugh Class B): 4 participants&#xD;
&#xD;
        -  Group with severe impairment (Child-Pugh Class C): 4 participants&#xD;
&#xD;
      An Internal Review Committee (IRC) will review the safety and PK data of encorafenib in&#xD;
      combination with binimetinib for group with normal hepatic function and group with moderate&#xD;
      hepatic impairment and make a recommendation prior to start group with severe impairment&#xD;
      enrolment. The Sponsor will determine whether it is safe and feasible to proceed with group&#xD;
      with severe impairment.&#xD;
&#xD;
      Participants will receive treatment doses according to their assigned group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Participants with hepatic impairment will be enrolled sequentially according to their severity.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Encorafenib Cmax</measure>
    <time_frame>Day 1 and Day 15: 0-8 hours post-dose</time_frame>
    <description>Maximum Observed Plasma Concentration of encorafenib expressed as total and unbound concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Encorafenib AUClast</measure>
    <time_frame>Day 1 and Day 15: 0-8 hours post-dose</time_frame>
    <description>Area Under the Plasma Concentration versus Time Curve from Time 0 to Time of Last Quantifiable Concentration of encorafenib expressed as total and unbound concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Encorafenib AUC(0-inf)</measure>
    <time_frame>Day 1 and Day 15: 0-8 hours post-dose</time_frame>
    <description>Area Under the Plasma Concentration versus Time Curve from Time 0 to Infinity of encorafenib expressed as total and unbound concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1 and Day 15: 0-8 hours post-dose</time_frame>
    <description>Time to Reach Maximum Plasma Concentration of encorafenib and its metabolite (LHY746) and binimetinib and its active metabolite (AR00426032)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>Day 15: 0-8 hours post-dose</time_frame>
    <description>Minimum Observed Plasma Concentration of encorafenib and its metabolite (LHY746) and binimetinib and its active metabolite (AR00426032) expressed as total and unbound concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Day 1 and Day 15: 0-8 hours post-dose</time_frame>
    <description>Terminal Phase Plasma Half-life of encorafenib and binimetinib and their metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day 1 and Day 15: 0-8 hours post-dose</time_frame>
    <description>Apparent Total Body Clearance of encorafenib and binimetinib and their metabolites as total and unbound concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Day 1 and Day 15: 0-8 hours post-dose</time_frame>
    <description>Apparent Volume of Distribution at Terminal Phase of encorafenib and binimetinib and their metabolites as total and unbound concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRCmax</measure>
    <time_frame>Day 1: 0-8 hours post-dose</time_frame>
    <description>Metabolic Ratio of Cmax of LHY746 to Cmax of encorafenib, Metabolic Ratio of Cmax of AR00426032 to Cmax of binimetinib Corrected for Molecular Weights</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRAUC</measure>
    <time_frame>Day 1: 0-8 hours post-dose. AUC will be AUC(0-inf) and/or AUClast depending on evaluability of AUC(0-inf).</time_frame>
    <description>Metabolic Ratio of AUC of LHY746 to AUC of encorafenib, Metabolic Ratio of AUC of AR00426032 to AUC of binimetinib Corrected for Molecular Weights</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>BRAF V600 Mutation</condition>
  <condition>Unresectable Melanoma</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group with normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate hepatic impairment (Child-Pugh Class B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with severe impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe impairment (Child-Pugh Class C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib + Binimetinib</intervention_name>
    <description>The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses</description>
    <arm_group_label>Group with normal hepatic function</arm_group_label>
    <other_name>Braftovi + Mektovi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib + Binimetinib</intervention_name>
    <description>A smaller dose than the dose approved for patients with normal hepatic function has been defined</description>
    <arm_group_label>Group with moderate hepatic impairment</arm_group_label>
    <other_name>Braftovi + Mektovi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib + Binimetinib</intervention_name>
    <description>A smaller dose than the dose approved for patients with normal hepatic function has been defined</description>
    <arm_group_label>Group with severe impairment</arm_group_label>
    <other_name>Braftovi + Mektovi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically/cytologically confirmed diagnosis of locally advanced, unresectable or&#xD;
             metastatic cutaneous melanoma or unknown primary melanoma&#xD;
&#xD;
          2. Presence of BRAF V600E or V600K mutation&#xD;
&#xD;
          3. ECOG PS of 0 or 1&#xD;
&#xD;
          4. Adequate bone marrow, organ function and laboratory parameters&#xD;
&#xD;
          5. Hepatic function criteria:&#xD;
&#xD;
               -  Group with normal hepatic function&#xD;
&#xD;
               -  Group with moderate hepatic impairment (Child-Pugh Class B)&#xD;
&#xD;
               -  Group with severe impairment (Child-Pugh Class C)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A calculated Child-Pugh score that showed impairment for a reason other than liver&#xD;
             dysfunction (e.g., cancer cachexia)&#xD;
&#xD;
          2. History or symptoms of encephalopathy (Grade II or worse)&#xD;
&#xD;
          3. Clinical evidence of severe ascites&#xD;
&#xD;
          4. History of surgical portosystemic shunt with complications&#xD;
&#xD;
          5. Active bleeding during the last 28 days prior to the first dose of study treatment&#xD;
&#xD;
          6. Anticoagulant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Arenberger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultni Nemocnice Kralovske Vinohrady, Czech Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa Boudribila</last_name>
    <phone>+33 5 34 50 60 98</phone>
    <email>asmaa.boudribila@pierre-fabre.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amandine Laurans</last_name>
    <phone>+33 5 34 50 62 04</phone>
    <email>amandine.laurans@pierre-fabre.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Pavla Pickova</last_name>
      <phone>+420 588 443 895</phone>
      <email>pavla.pickova@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Bohuslav Melichar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <last_name>Barbora Roudnicka</last_name>
      <phone>+420 267 162 633</phone>
      <email>roudnickakh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Petr Arenberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Irst</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Flavia Pagan</last_name>
      <phone>+39 0543 739423</phone>
      <email>flavia.pagan@irst.emr.it</email>
    </contact>
    <contact_backup>
      <last_name>Giorgia Gentili</last_name>
      <phone>+39 0543 739423</phone>
      <email>giorgia.gentili@irst.emr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Massimo Guidoboni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Elisa Ibba</last_name>
      <phone>+39 0577 586056</phone>
      <email>elisa.ibba@ao-sienatoscana.it</email>
    </contact>
    <investigator>
      <last_name>Michele Maio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Candon</last_name>
      <phone>+34 600162731</phone>
      <email>mariacandon.oncomacarena@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luis De La Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Iris Ramos</last_name>
      <phone>0034963131800</phone>
      <phone_ext>437635</phone_ext>
      <email>ramos_iri@gva.es</email>
    </contact>
    <contact_backup>
      <last_name>Vicente Castellano</last_name>
      <phone>0034963187527</phone>
      <email>castellano_vic@gva.es</email>
    </contact_backup>
    <investigator>
      <last_name>Alfonso Berrocal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

